Spatz FGIA, Inc. is a US-based medical device company focused on the development of a non-surgical, less invasive and safe device for the treatment of obesity.
Obesity is a worldwide health crisis, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been associated with significant morbidity and mortality, driving the pursuit of a non-surgical weight loss solution.
Spatz Medical was founded in 2005 by Dr. Jeffrey Brooks, a US board-certified gastroenterologist with 25 years of clinical experience, who has held an academic position at Columbia University.
Spatz FGIA‘s flagship product, the Spatz3™ Adjustable Balloon System, is a fluid-filled adjustable balloon approved for 1 year – a first in gastric balloons. The 15-minute out-patient procedure reduces stomach capacity and prolongs stomach emptying time which assist patients in eating less. Patients are discharged home within several hours after insertion.
The gastric balloon has been designed and manufactured under GMP (good manufacturing practice) conditions in an ISO 13485 certified facility specializing in the fabrication of high quality silicone medical and technical products.
The Spatz3 Adjustable Balloon System has been granted CE Mark for 1-year implantation and is available for sale in many parts of the world. The Spatz balloon is the first intragastric balloon that is both adjustable and approved for 1 year implantation. For specific details on availability in your area, please see the Contact Us page.